Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity

This publication has 29 references indexed in Scilit:

• Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells
  The Journal of Experimental Medicine, 2004
• gp100209–2M Peptide Immunization of Human Lymphocyte Antigen-A2+ Stage I-III Melanoma Patients Induces Significant Increase in Antigen-Specific Effector and Long-Term Memory CD8+ T Cells
  Clinical Cancer Research, 2004
• Short Communication: CD4⁺T Cells and Monocytes Elicited by Immunization of Rhesus Monkeys with Antigen-Pulsed Dendritic Cells Control SIV Replication
  AIDS Research and Human Retroviruses, 2002
• A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection
  International Journal of Cancer, 2001
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines
  Science, 1994
• Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
  The Journal of Experimental Medicine, 1994
• Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
  Published by American Medical Association (AMA) ,1994
• Induction of CD8⁺ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells
  International Immunology, 1993
• Antigen Recognition by Class I-Restricted T Lymphocytes
  Annual Review of Immunology, 1989